Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013, Article ID 295132, 18 pages
Review Article

IL-17 in the Rheumatologist’s Line of Sight

1UMR-CNRS 5164, Composantes Innées de la Réponse Immunitaire et de la Différenciation, Université Bordeaux Segalen, 146 rue Léo Saignat, 33076 Bordeaux, France
2Département de Rhumatologie, Hôpital Pellegrin, CHU de Bordeaux, place Amélie-Raba-Léon, 33076 Bordeaux, France
3INSERM U1035–Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen, 146 rue Léo Saignat, 33076 Bordeaux, France

Received 30 April 2013; Accepted 27 June 2013

Academic Editor: Michael Greenwood

Copyright © 2013 Marie-Elise Truchetet et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Over the past decades, the identification of several new cytokines, including interleukin (IL)-17 and IL-23, and of new T helper cell subsets, including Th17 cells, has changed the vision of immunological processes. The IL-17/Th17 pathway plays a critical role during the development of inflammation and autoimmunity, and targeting this pathway has become an attractive strategy for a number of diseases. This review aims to describe the effects of IL-17 in the joint and its roles in the development of autoimmune and inflammatory arthritis. Furthermore, biotherapies targeting directly or indirectly IL-17 in inflammatory rheumatisms will be developed.